ATLANTA, Jan. 09, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA). The lawsuit alleges that the Company’s registration statement issued in connection with its IPO was false and/or misleading because Defendants failed to disclose safety concerns related to its lead product candidate, azelaprag. If you bought shares of BioAge on or after September 26, 2024 and you suffered a significant loss on that investment, you ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Investors have until March 10, 2025, to ask the Court to be appointed to lead the case ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=121492&from=4 CLASS PERIOD: This lawsuit is on ...

NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether BioAge and certain of its officers and/ ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) securities on BioAge Labs’ initial public offering (the “IPO”) held on September 26, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the ...

NEWTOWN, Pa., Jan. 8, 2025 /PRNewswire/ -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of all investors of BioAge Labs, Inc. (NASDAQ: BIOA) who purchased stock pursuant and/or traceable to BioAge Labs' registration statement issued in connection with the company's initial public offering (the "IPO") on September 26, 2024. To join this case, go HERE.Investors who purchased BioLabs stock may move the U.S. District Court for the Northern of Californ ...

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and/or traceable to BioAge Labs' registration statement issued in connection with BioAge Labs' initial public offering (the "IPO") held on September 26, 2024, have until March 10, 2025 to seek appointment as lead plaintiff of the BioAge Labs class action lawsuit.  Captioned Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), th ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioAge securities pursuant and/or traceable to BioAge’s registration statement for the initial public offering hel ...

SAN FRANCISCO, Jan. 3, 2025 /PRNewswire/ -- Shares of BioAge (NASDAQ: BIOA) have plummeted since the company's December 6 announcement of the discontinuation of a Phase 2 trial for its weight-loss drug azelaprag due to safety concerns. The abrupt halt comes just a little over two months after the company raised $198 million in a highly anticipated initial public offering in late September.Hagens Berman has opened an investigation into whether BioAge's IPO documents may have contained misstatements or omissi ...

NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether BioAge and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around September 26 ...